Question 1

How many UTIs constitute a recurrent UTI?

Accepted Answer

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Question 2

Why do I keep getting UTIs even after taking antibiotics?

Accepted Answer

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Question 3

Can recurrent UTIs be prevented?

Accepted Answer

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Question 4

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

Accepted Answer

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Question 5

Is long-term antibiotic use for UTI prevention safe?

Accepted Answer

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Question 6

Does Atlas IDP accept insurance for recurrent UTI treatment?

Accepted Answer

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Protect yourself from common contagious viruses, unlike Ebola, with these expert tips

The State of US Vaccine Policy — May 28, 2026

Quick takes: Death toll from USAID cuts, withdrawal of chikungunya vaccine, funding for updated Ebola vaccine

Early Release – Phenotypic and Genomic Characterization of Antimicrobial-Resistant Neisseria gonorrhoeae of Public Health Concern – Volume 32, Number 6—June 2026 – Emerging Infectious Diseases journal

Schedule an Appointment

Quick Links

Patient Forms

Contact Us